Author

Paul Atigbire

Carl von Ossietzky Universität OldenburgORCID 0000-0001-9032-4583Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Charlotte Luise Kluth· 1 shared Christoph Jüschke· 1 shared Dennis Kastrati· 1 shared Jannis Marticke· 1 shared John NeidhardtiD· 1 shared Julia Milena Brinkhoff· 1 shared Muhammad Usman· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Charlotte Luise Kluth

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cell BiologybioRxivPreprintMay 9, 2025

The human-specific RPGR isoform RPGRs14/15 and the clinically approved Rho/ROCK inhibitor Ripasudil represent therapeutic options to address RPGR-associated defects.

Muhammad Usman, Paul Atigbire, Dennis Kastrati…·John Neidhardt

This study identifies the human-specific RPGR isoform RPGRs14/15 and the drug Ripasudil as potential therapies for RPGR-associated retinal degeneration by rescuing ciliary and actin defects in RPGR mutant cells.

DOI 10.1101/2025.05.09.653106

humanproteomics

𝕏 PostBluesky